Ngar Yee Louie Buys 81,699 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie acquired 81,699 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average cost of $1.22 per share, for a total transaction of $99,672.78. Following the acquisition, the director directly owned 1,248,888 shares in the company, valued at $1,523,643.36. This represents a 7.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

MAIA Biotechnology Stock Up 8.8%

MAIA stock opened at $1.48 on Thursday. The stock has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.50. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $2.74. The firm has a market capitalization of $54.80 million and a PE ratio of -2.03.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). On average, equities research analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 EPS for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

Several large investors have recently added to or reduced their stakes in the business. Centerpoint Advisory Group bought a new stake in MAIA Biotechnology during the second quarter valued at approximately $28,000. Geode Capital Management LLC lifted its holdings in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares during the last quarter. Centric Wealth Management grew its position in MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after acquiring an additional 505,150 shares in the last quarter. Marshall Wace LLP bought a new position in MAIA Biotechnology in the second quarter valued at $29,000. Finally, Jane Street Group LLC purchased a new stake in MAIA Biotechnology during the second quarter valued at about $52,000. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.